On May 26, 2021, The U.S. Department of Health & Human Services posted an update regarding the use of Bamlanivimab and Etesevimab monoclonal antibody therapy. Distribution for these products have been paused in Illinois, Massachusetts, Arizona, California, Florida, Indiana, Oregon, and Washington until further notice. Please read the full update below for more information.
